| 2.17 -0.1 (-4.41%) | 12-06 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.45 |
1-year : | 4.01 |
| Resists | First : | 2.95 |
Second : | 3.44 |
| Pivot price | 2.63 |
|||
| Supports | First : | 2.17 |
Second : | 1.8 |
| MAs | MA(5) : | 2.41 |
MA(20) : | 2.6 |
| MA(100) : | 2.87 |
MA(250) : | 5.79 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 2.7 |
D(3) : | 10 |
| RSI | RSI(14): 37.2 |
|||
| 52-week | High : | 23.68 | Low : | 2.17 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ VAPO ] has closed above bottom band by 8.5%. Bollinger Bands are 36.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.35 - 2.37 | 2.37 - 2.38 |
| Low: | 2.12 - 2.15 | 2.15 - 2.17 |
| Close: | 2.14 - 2.18 | 2.18 - 2.21 |
Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor, which provides compressed air necessary to run the precision flow systems; aerosol aeroneb adaptor to facilitate delivery of ultrasonic aerosolized medication; aerosol disposable patient circuit that is designed to streamline the provision of continuous and intermittent delivery of aerosol medication; and tracheostomy adaptors. In addition, Vapotherm, Inc. offers ProSoft cannula to provide gentle contact with the skin; and disposable products comprising single-use disposables and nasal interfaces, as well as Oxygen Assist Modules, which helps clinicians maintain oxygen levels within a target range. The company sells its products to hospitals. Vapotherm, Inc. was founded in 1993 and is headquartered in Exeter, New Hampshire.
Fri, 10 Nov 2023
Vapotherm, Inc. (NYSE:VAPO) Q3 2023 Earnings Call Transcript - Yahoo Finance
Wed, 08 Nov 2023
Vapotherm: Q3 Earnings Snapshot - Houston Chronicle
Wed, 08 Nov 2023
Vapotherm: Q3 Earnings Snapshot - San Francisco Chronicle
Wed, 04 Oct 2023
Computational Fluid Dynamics (CFD) modeling further distinguishes Vapotherm High Velocity Therapy from generic ... - Business Wire
Mon, 25 Sep 2023
Pilot Study demonstrates Vapotherm HVNI technology is more effective than standard oxygen therapy for treatment of ... - Business Wire
Wed, 08 Feb 2023
Vapotherm Announces $23 Million Private Placement - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical Devices
|
|
| Shares Out | 6 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 491 (K) |
| Shares Short P.Month | 326 (K) |
| EPS | -14.33 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -7.74 |
| Profit Margin | -102.8 % |
| Operating Margin | -62.8 % |
| Return on Assets (ttm) | -31.4 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 12 % |
| Gross Profit (p.s.) | 2.96 |
| Sales Per Share | 11 |
| EBITDA (p.s.) | -7.12 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -31 (M) |
| Levered Free Cash Flow | -22 (M) |
| PE Ratio | -0.16 |
| PEG Ratio | -0.1 |
| Price to Book value | -0.29 |
| Price to Sales | 0.19 |
| Price to Cash Flow | -0.43 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|